“I would say that the fall-through on that is probably going to be the pretty typical 35% to 40% fall through.”

In context

“ocess. And then looking forward to 2023, we would see that going from $800 million to $500 million. Vijay Kumar: Appreciate the color, Rainer. Matt, One quick one for you. Based on current FX rates, and I think your assumptions on pricing for next year, how should we think about incremental margins for '23? Matt McGrew: For '23? Vijay Kumar: Yes. Matt McGrew: I'm going to go ahead and ask that we get through Q4 here and see where it is. If I had to guess on the FX margins today, I would have been wrong a quarter ago and wrong the quarter before that. So we'll give you a full update on '23. I mean I think you've seen where the margins have gone to. You know that we're going to have an FX headwind next year on the top line of probably, call it, $800 million. So you can probably start there. I would say that the fall-through on that is probably going to be the pretty typical 35% to 40% fall through. And that could be a little bit better or worse depending on where that revenue actually comes in from a mix perspective. But that's probably the best I can give you now, what we know what the rates are. But from a full margin perspective, I'll have to wait until we get a little bit closer and to our guidance in '23. Operator: We'll take our next question from Dan Brennan with Cowen and Company. Dan Brennan: If I may, just Rainer, I know on the last call, and it was already addressed in some of the Bioprocessing information. But when you look more broadly, obviously, you see a lot of mixed signals on the macro. Last call, you had suggested all-in organic mid-single and if you factor in the COVID would roll off low single digits, like any updated thinking on how you think about that? I know”